Insider Buying: CSL (ASX:CSL) Insider Buys 3,400 Shares of Stock

CSL Limited (ASX:CSL) insider Brian Daniels purchased 3,400 shares of the business’s stock in a transaction on Tuesday, November 18th. The stock was purchased at an average price of A$29.34 per share, for a total transaction of A$99,745.80.

CSL Stock Performance

The company has a quick ratio of 1.68, a current ratio of 1.86 and a debt-to-equity ratio of 64.46. The stock has a market capitalization of $77.43 billion, a price-to-earnings ratio of 28.02, a P/E/G ratio of 1.29 and a beta of 0.32.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.